Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

PsychoGenics CEO explores CNS drug development trends

By Brian Buntz | February 4, 2023

In the late 2000s, many companies, particularly Big Pharma, exited the field of central nervous system (CNS) drug development and, particularly psychiatry. “Big Pharma exited the space because they were facing their patent cliff at the time and had to make some critical decisions about where to invest their resources,” said Emer Leahy, CEO of the contract research organization PsychoGenics. “Oncology won out over CNS,” she added.

In a recent interview, Leahy opened up on the current renaissance in CNS drug development, including the role of AI while also touching on the impact of the Inflation Reduction Act on the field.

Innovation in next-generation medicines for neuropsychiatric disorders continues

Emer Leahy

Emer Leahy

Interest in ketamine for mood disorders has been a game-changer for CNS drug development. “Ketamine has shown to be effective in populations where they have been resistant to all therapies to date,” Leahy said. “It’s effective almost immediately or very quickly. It can be administered once a week or once a month.”

Although widely used off-label for conditions like depression and anxiety, ketamine has also benefited from Johnson & Johnson’s commercialization of the stereoisomer esketamine, which won FDA approval in 2019.

The recent success of Compass Pathways in using psilocybin as an antidepressant has also helped lead to a resurgence of interest in this area. “Companies are now researching second- and third-generation psychedelics, including compounds that have similar therapeutic qualities but without the dissociative or hallucinogenic effects,” Leahy said.

Some companies will decrease the number of drugs in their pipeline

After the Inflation Reduction Act was passed, a number of companies such as Alnylam Pharmaceuticals already have pared back their pipelines. “We are likely to see this trend continue in 2023 as companies make crucial decisions about where to put their resources,” Leahy said.

COVID also changed how we do drug development. In particular, it accelerated adoption of decentralized clinical trials. We are going to see a lot more of that.

AI poised to fuel more progress in CNS drug development

“AI is enormously important,” Leahy said. The technology has promise in streamlining everything from drug discovery to clinical trials.

While Leahy acknowledged the hype around AI, she notes that PsychoGenics’ platform has been clinically validated.

Leahy points to the discovery of ulotaront as a case in point. “The Phase 2 results for ulotaront were very positive for positive and negative symptoms of schizophrenia,” she said. “It had placebo-like side effects, and it improved some features that placebo did not, including anxiety, in a couple of cases. “

Based on an analysis of the Phase 2 clinical trial, Sunovion with their partner Otsuka, has decided to investigate ulotaront for major depressive disorder and generalized anxiety disorder. The Phase 2/3 depression has already started.

More inspiration from psychedelics to create novel compounds

PsychoGenics is also finding inspiration from psychedelics to develop new compounds. “Our platform analyzes the behavior of mice with novel compounds to compare their behavioral responses with reference compounds and psychedelics (such as ketamine, psilocybin and MDMA) in our database,” Leahy said. “The platform screens those novel compounds and compares their profiles to individual drugs in the database.”

PsychoGenics has used the platform to identify compounds that resemble classic psychedelic compounds such as psilocybin, but that don’t target 5-HT2A as a mechanism. “They do not cause the induction of head shakes in mice, which is suggestive of a dissociative effect,” Leahy said.

While more research is needed, it’s “promising to see compounds having these profound antidepressant behavioral profiles that resemble what you see with something like psilocybin and without some of the side effects,” Leahy said. “We’re pretty excited about where that research is headed.”

PsychoGenics’ researchers get excited when novel compounds show therapeutic signatures, as it increases their confidence in potentially starting a new discovery program. “Our focus is currently on understanding the chemistry behind positive behavioral responses and how it leads to novel therapeutic outcomes,” Leahy said. “We aim to explore untapped areas of chemistry space to inform our therapeutic decisions.”


Filed Under: Psychiatric/psychotropic drugs
Tagged With: CNS drug development
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Measuring Psilocybin Magic Mushroom Micro Doses in Laboratory for A Scientific Experiment
After decades of trial failures in chemotherapy-linked neuropathy, psilocybin shows promise in preventing it in mice 
J&J poster puts Spravato remission data at center of treatment-resistant-depression growth push
Compass Pathways
First Phase 3 psilocybin data clears the bar for treatment-resistant depression, but how high was the bar?
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE